DOIIF
Financiado
Development of small molecule OGG1 Inhibitor and proof of concept in bleomycin i...
Development of small molecule OGG1 Inhibitor and proof of concept in bleomycin induced disease model of Inflammation and pulmonary Fibrosis
Fibrosis in response to tissue damage or persistent inflammation is a pathological hallmark of many chronic degenerative diseases where
Idiopathic Pulmonary Fibrosis (IPF) is one of the most severe diseases. IPF is a progressive c...
Fibrosis in response to tissue damage or persistent inflammation is a pathological hallmark of many chronic degenerative diseases where
Idiopathic Pulmonary Fibrosis (IPF) is one of the most severe diseases. IPF is a progressive condition with unknown etiology and a median
survival of three years from diagnosis. Current medical treatment is limited to slowing down the disease and thus there is still a high unmet medical need. OGG1 enzyme has a major role in DNA repair in conditions of oxidative stress and also in regulation of gene transcription involved in immune responses. In our ERC grant we developed a first-in class OGG1 inhibitor that protects from exaggerated immune response induced by the proinflammatory mediator TNFα. We have shown with this compound in
several airway inflammation models, that inhibition of OGG1 results in a significant down regulation of mediators associated with inflammation and fibrosis, reduced infiltration of immune cells in lungs and increased alveolar integrity compared with control. We have developed a large number of compounds and in this proposal we aim to demonstrate proof of concept (PoC) for the most promising compound in an established model of pulmonary fibrotic diseases in order to select a candidate drug (CD). Our plan is to establish collaboration with industrial partners for further development in order take one compound through preclinical development and clinical phase 1/2a for further commercialization. Treatment with a potent OGG1 inhibitor has the potential to attenuate or resolve the progress of the disease, alone or in combination with existing therapies and increase survival of IPF patients and reduce healthcare costs.
ver más
Duración del proyecto: 21 meses
Fecha Inicio: 2020-07-30
Fecha Fin: 2022-04-30
Fecha Fin: 2022-04-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-04-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2020-POC:
Call for proposals for ERC Proof of Concept Grant
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
KAROLINSKA INSTITUTET
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.83M€ |
Participante